These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 9531029)

  • 1. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
    Gori AM; Pepe G; Attanasio M; Falciani M; Abbate R; Prisco D; Fedi S; Giusti B; Brunelli T; Giusti B; Brunelli T; Comeglio P; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
    Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
    Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
    Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome.
    Rogolino A; Coccia ME; Fedi S; Gori AM; Cellai AP; Scarselli GF; Prisco D; Abbate R
    Blood Coagul Fibrinolysis; 2003 Apr; 14(3):277-82. PubMed ID: 12695751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma tissue factor and tissue factor pathway inhibitor levels in acute myocardial infarction patients with no-reflow during percutaneous coronary intervention].
    Xu P; Qi XY; Li CH; Zhang JH; Liu DM; Liu J; Wang WL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Nov; 36(11):1013-5. PubMed ID: 19102916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microparticles (MPs), tissue factor (TF) and tissue factor inhibitor (TFPI) in cord blood plasma. A preliminary study and literature survey of procoagulant properties of MPs.
    Uszyński M; Zekanowska E; Uszyński W; Kuczyński J; Zyliński A
    Eur J Obstet Gynecol Reprod Biol; 2011 Sep; 158(1):37-41. PubMed ID: 21664032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
    Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
    Agledahl I; Brodin E; Svartberg J; Hansen JB
    Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.
    Al-Nozha MM; Abdel-Gader AG; Arafah MR; Al-Maatouq MA; Al-Shahid MS; Al-Harthi SS; Khan NB; Abdullah MA
    Saudi Med J; 2005 Jun; 26(6):937-42. PubMed ID: 15983678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of tissue factor pathway inhibitor-1 on no-reflow in a rabbit model].
    Luo JG; Chen YD; Tian F; Wang CH; Lü Y; Yang XX; Lü SZ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec; 37(12):1113-8. PubMed ID: 20193184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated tissue factor circulating levels in children with hemolytic uremic syndrome caused by verotoxin-producing E. coli.
    Kamitsuji H; Nonami K; Murakami T; Ishikawa N; Nakayama A; Umeki Y
    Clin Nephrol; 2000 May; 53(5):319-24. PubMed ID: 11305804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease.
    Jafarzadeh A; Esmaeeli-Nadimi A; Nough H; Nemati M; Rezayati MT
    Anadolu Kardiyol Derg; 2009 Apr; 9(2):75-83. PubMed ID: 19357047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
    Naumnik B; Borawski J; Chyczewski L; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
    Adams MJ; Palatinus AA; Harvey AM; Khalafallah AA
    Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
    Eling M; Stephens AC; Oragui EE; Rivers RP; Levin M
    Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.
    Amengual O; Atsumi T; Khamashta MA; Hughes GR
    Thromb Haemost; 1998 Feb; 79(2):276-81. PubMed ID: 9493575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early heparin administration attenuates tissue factor-mediated thrombin generation during simulated cardiopulmonary bypass.
    Morizumi S; Hiramatsu Y; Matsuzaki K; Goto Y; Sato S; Abe M; Kato H; Matsubara M; Sakakibara Y
    J Card Surg; 2014 Jan; 29(1):35-40. PubMed ID: 24266905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.